Analysis of N6-Methyladenosine Methylome in Adenocarcinoma of Esophagogastric Junction [PDF]
Frontiers in Genetics, 2022 Background: From previous studies, we found that there are more than 100 types of RNA modifications in RNA molecules. m6A methylation is the most common.
Jia-Bin Huang +6 more
doaj +2 more sources
Integrative proteomic characterization of adenocarcinoma of esophagogastric junction [PDF]
Nature Communications, 2023 The molecular subtypes of adenocarcinoma of the esophagogastric junction (AEG) remain to be identified. Here, the authors perform proteogenomic characterisation of AEG tumours with paired normal adjacent tissues and suggest three proteomic subtypes and ...
Shengli Li +18 more
doaj +2 more sources
Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis [PDF]
BMC Surgery, 2021 Background To analyze whether neoadjuvant chemoradiotherapy (nCRT) could improve the survival for patients with adenocarcinoma of the esophagogastric junction compared with neoadjuvant chemotherapy (nCT).
Jing Li +7 more
doaj +2 more sources
Esophageal intramural metastasis from adenocarcinoma of esophagogastric junction: a case report and literature review [PDF]
Frontiers in OncologyBackgroundIntramural metastasis from adenocarcinoma of the esophagogastric junction (AEG) to the esophagus is a rare event and is associated with a poor prognosis.Case summary and literature reviewWe report a 77-year-old male patient diagnosed with AEG ...
Yongfen Ma +4 more
doaj +2 more sources
CT-based radiomics nomogram to predict response of advanced adenocarcinoma of esophagogastric junction to neoadjuvant chemotherapy [PDF]
Insights into ImagingObjective To establish and validate a CT-based radiomics model to predict the response of adenocarcinoma of the esophagogastric junction (AEG) to neoadjuvant chemotherapy (NAC).
Chuan-qinyuan Zhou +7 more
doaj +2 more sources
Oral microbial profile polymorphisms predict early Siewert II adenocarcinoma of esophagogastric junction [PDF]
BMC MicrobiologyBackground Dysbiosis of the oral microbiota has been shown to be associated with the development of esophageal and gastric cancer. Nevertheless, little research explores how oral microbiota might contribute to the occurrence and progression of ...
Fangrui Zou +6 more
doaj +2 more sources
Integrated single-cell RNA sequencing reveals the tumor heterogeneity and microenvironment landscape during liver metastasis in adenocarcinoma of esophagogastric junction [PDF]
Frontiers in ImmunologyBackgroundAdenocarcinoma of the esophagogastric junction (AEGJ) is a highly aggressive tumor that frequently metastasizes to the liver. Understanding the cellular and molecular mechanisms that drive this process is essential for developing effective ...
Junrui Xu +6 more
doaj +2 more sources
The Early Diagnostic Value of Serum Interleukin-8 in Esophagogastric Junction Adenocarcinoma
Cancer Control, 2021 Background: Esophagogastric junction adenocarcinoma (EJA) is one of the most common malignant tumors of digestive tract with high mortality worldwide. Given a lack of early diagnosis biomarkers, the prognosis of EJA is poor.
Enmin Li, Li-Yan Xu, Yi-Wei Xu
exaly +2 more sources
Surgical principles for optimal treatment of esophagogastric junction adenocarcinoma
Annals of Gastroenterological Surgery, 2019 The incidence of esophagogastric junction (EGJ) adenocarcinoma is increasing worldwide. Management of these tumors remains controversial given their unique location between the esophagus and the stomach.
Tamar B Nobel, Daniela Molena
exaly +2 more sources
Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy) [PDF]
BMC CancerBackground For resectable adenocarcinoma of the esophagogastric junction (AEG), current treatment exploration primarily focuses on perioperative chemotherapy regimens combined with PD-1/PD-L1 inhibitors, but the long-term survival benefits of still ...
Yingyi Li +5 more
doaj +2 more sources